NewswireToday - /newswire/ -
Clayton, MO, United States, 2006/04/19 - Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that the Health On the Net (HON) Foundation has accredited the Nutra Pharma website as being compliant with the HONcode.
The Health On the Net Foundation is a Geneva-based non-profit organization established to promote and guide the deployment of useful and reliable online medical and health information on the web. Established in 1995, the Health On the Net Foundation was founded by a group of leading telemedicine professionals.
“We are honored to receive this prestigious accreditation from the HON Foundation in Switzerland,” explained Rik J Deitsch, CEO of Nutra Pharma Corporation. “By following the HONcode set of principals, visitors to our website know that they are receiving credible and reliable information. We are now working with the World Health Organization and the Stop TB Partnership. Understanding that there are an increasing number of organizations relying on the data from the HON Foundation, our accreditation will ensure our future acceptance within these organizations,” he concluded.
Previous recipients of the HONcode accreditation include: WebMD, Mayo Clinic, Johns Hopkins Department of Medical Emergency, and Mount Sinai Hospital.
About the Health on the Net Foundation
The Health On the Net Foundation is the leading organization promoting and guiding the deployment of useful and reliable online medical and health information, and its appropriate and efficient use. Created in 1995, HON is a non-profit, non-governmental organization, accredited to the Economic and Social Council of the United Nations.
About Nutra Pharma Corp.
Nutra Pharma Corp. (NutraPharma.com) is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The accreditation by the HON Foundation should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Sec.GOV. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.